Obicetrapib (CETP inhibitor for dyslipidemia)

[Bicep]

I’m a little slow here. Does it increase HDL by a lot?

[jeanbaptiste]

yes it does, almost x2 the baseline

[RapamycinCurious]

@Bicep

I’m a little slow here. Does it increase HDL by a lot?

Probably irrelevant (HDL level is not causally involved in ASCVD), but yes:

Obicetrapib (CETP inhibitor for dyslipidemia)

The one year — apparently final — results of the BROOKLYN Phase 3 trial are even better than the interim data: Phase 3 BROOKLYN Trial Results The BROOKLYN trial met its primary endpoint, achieving an LS mean reduction of 36.3% (p < 0.0001) compared to placebo at day 84, which was sustained at day 365 with an LS mean LDL-C reduction of 41.5% (p < 0.0001). Secondary efficacy endpoints, including lipoprotein(a) (“Lp(a)”), which was 45.9% (p<0.0001) compared to placebo at day 84 and 54.3% (p=0.16) at day 365, apolipoprotein B (“ApoB”), high-density lipoprotein cholesterol (“HDL-C”) and non-HDL-C met statistical significance and results were consistent with data reported from NewAmsterdam’s prior clinical trials. The p-value for the LS mean for all secondary endpoints compared to placebo was <0.0001 following 84 days of treatment with obicetrapib. [Screenshot 2024-11-18 at 1.03.18 PM] Obicetrapib was observed to be well tolerated, with safety results comparable to placebo and no incre…

[adssx]

@RapamycinCurious

Probably irrelevant (HDL level is not causally involved in ASCVD), but yes:

Irrelevant for ASCVD but very relevant for other conditions. That’s why they’re trying to repurpose obicetrapib.

[Bicep]

I suppose you don’t get info on all cause mortality until it’s been out for 10 years or so, but Cardiovascular events are worse and it gives you diabetes.

Am I reading that right?

[Virilius]

There are twice as many people in the treatment group as on placebo. Check out the number right next to it.

[RapamycinCurious]

@Virilius

@Bicep

I suppose you don’t get info on all cause mortality until it’s been out for 10 years or so, but Cardiovascular events are worse and it gives you diabetes.

Am I reading that right?

There are twice as many people in the treatment group as on placebo. Check out the number right next to it.

Right: Look at the top of the columns. There are 110 people on placebo and 236 people on Obi. The numbers for each outcome are first the absolute number (n) and then the percentage (%) of the subjects in that group who had the event. Obi is nominally lower for everything, though there aren’t statistics in this screenshot.

[Bicep]

Thanks to all. I’ve had a really busy day and just got back to look at this. It’s a couple percent better at all those, should gain traction for small LDL, lp(a), aboB, and several others. Looks like a good drug. It looks like they mostly tested it on people already on statin. Very interesting to see what happens without.

[adssx]

Check this larger trial, after just one year there’s positive (but not statistically significant) signal for all-cause mortality: Obicetrapib (CETP inhibitor for dyslipidemia) - #131 by adssx

[RapAdmin]

A fixed-dose oral combination of the CETP inhibitor obicetrapib and ezetimibe lowered LDL cholesterol (LDL-C) levels by nearly 50% at 12 weeks compared with placebo in patients with or at high risk for atherosclerotic cardiovascular disease (ASCVD) in the phase 3 TANDEM study.

“This is the first phase 3 trial evaluating the LDL cholesterol-lowering efficacy of a combination of this investigational CETP inhibitor with the established lipid-lowering drug ezetimibe in the setting of ASCVD,” says the study’s first author, Ashish Sarraju, MD, a Cleveland Clinic cardiologist who served as principal investigator. The TANDEM results were presented by Cleveland Clinic’s Steven Nissen, MD, chair of the trial’s executive steering committee, at the European Atherosclerosis Society Congress in Glasgow. They were simultaneously published in The Lancet.

Obicetrapib-Ezetimibe Combo Therapy Halves LDL Cholesterol Levels Relative to...